Ratos portfolio company TFS HealthScience has partnered with Swedish biotech company VERIGRAFT to support a pivotal Phase II/III trial of its personalized vascular therapy, P‑TEV.

TFS HealthScience will provide full-service clinical research support for the Phase II/III trial, evaluating safety, function and long-term performance in a larger patient population, reflecting the complexity of advanced therapy medicinal products (ATMPs).

“We are proud that this collaboration underscores TFS HealthScience’s ability to deliver complex clinical trials and support the development of innovative therapies addressing significant unmet medical needs,” says Gustaf Salford, CEO of Ratos.

About TFS HealthScience
TFS HealthScience is a full-service, global Contract Research Organization (CRO) that partners with biotechnology and pharmaceutical companies to advance innovative treatments and improve patient outcomes. TFS operates in 40 countries and delivers tailored clinical research services in specialized therapeutic areas, including dermatology, internal medicine, neuroscience, oncology and ophthalmology. Dedicated to empowering partners and enriching lives, TFS offers flexible clinical development and resourcing solutions that combine global reach with the agility and responsiveness of a mid-sized CRO. TFS HealthScience reported net sales of SEK 1,177m in 2025 and is led by CEO Markus Granlund.

Ratos holds a 100 percent ownership stake in TFS HealthScience.

For more information, please contact:
Katarina Grönwall, VP Communications & Sustainability
+46 70 300 35 38, katarina.gronwall@ratos.com

About Ratos
Ratos is a Swedish publicly listed investment company focused on long-term, active ownership. It holds majority and minority stakes in Nordic companies. In 2025, net sales totalled SEK 19 billion and adjusted EBITA SEK 1.9 billion. Ratos has approximately 9,100 employees and is headquartered in Stockholm, Sweden.

Attachments
Press release